Pentax Medical, a division of Hoya Corporation, is a leading provider of innovative medical imaging solutions, headquartered in Japan. Established in 1919, the company has a rich history of advancements in endoscopy and minimally invasive surgical technologies, serving healthcare professionals across the globe, particularly in Europe, Asia, and North America.
Specialising in endoscopic equipment, Pentax Medical offers a range of products, including high-definition endoscopes and imaging systems that enhance diagnostic accuracy and patient outcomes. Their commitment to quality and innovation has positioned them as a trusted partner in the medical community, with notable achievements in developing user-friendly devices that prioritise patient safety and comfort. With a strong market presence, Pentax Medical continues to lead the way in transforming healthcare through cutting-edge technology.
+23 vs industry average
Pentax Medical’s score of 50 is lower than 48% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Pentax Medical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medical Device Manufacturing has typical carbon intensity
Industry performance
The Medical Device Manufacturing industry has reduced its overall emissions by 18% since 2019
Reported emissions
No reported emissions data is available for Pentax Medical yet.
Pentax Medical's reported carbon emissions
In 2025, Pentax Medical reported total carbon emissions of approximately 788,000 kg CO2e, a decrease from about 866,000 kg CO2e in 2023. The emissions breakdown for 2025 includes 52,000 kg CO2e from Scope 1, 29,000 kg CO2e from Scope 2, and a significant 707,000 kg CO2e from Scope 3 emissions. This trend indicates a commitment to reducing overall emissions, particularly in Scope 3, which often represents the largest share of a company's carbon footprint.
In 2022, the company recorded total emissions of about 886,000 kg CO2e globally, with similar Scope 1 and Scope 2 figures of 52,000 kg CO2e and 29,000 kg CO2e, respectively. However, Scope 3 emissions were notably higher at approximately 804,000 kg CO2e.
Despite these figures, Pentax Medical has not publicly disclosed specific reduction targets or initiatives, nor does it appear to have set Science-Based Targets (SBTi) or other formal climate pledges. The emissions data is cascaded from its parent company, HOYA Corporation, indicating a corporate commitment to sustainability at multiple levels.
Overall, while Pentax Medical has shown a reduction in emissions from 2023 to 2025, the absence of defined reduction targets suggests an area for potential improvement in their climate strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Pentax Medical’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Pentax Medical yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from HOYA Corporation
Carbon Disclosure Project
Inherited from HOYA Corporation
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from HOYA Corporation
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Pentax Medical
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project